Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, Overland Park, KS, US) sits down to discuss the findings of the STROKE-VT Trial, which investigated the use of aipaxaban in reducing blood clots and stroke risk after an ablation procedure.
Questions:
1. Please summarise the aim, study design and endpoints?
2. What were your major findings?
3. What further research is required?
4. What are your take-home messages?
Recorded remotely from Overland Park, KS, US, 2021.
Editor: Jordan Rance
Radcliffe Group is a specialist provider of Cardiovascular, Renal and Metabolic (CVRM) content, The Radcliffe Group offers physicians access to content through a variety of media formats stemming from industry-leading peer-reviewed research journals, video interviews, live events and online medical courses.
